


DRUG METABOLISM *AND* DISPOSITION



A Publication of the
American Society for Pharmacology
and Experimental Therapeutics

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

June 2008

Vol. 36, No. 6

CONTENTS

CENTENNIAL PERSPECTIVE

- The Development of Drug Metabolism Research as Expressed in the Publications of ASPET: Part 2, 1959–1983. *Patrick J. Murphy* **981**

SHORT COMMUNICATIONS

- The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. *Hei-Young Ku, Hee-Jeong Ahn, Kyung-Ah Seo, Hyunmi Kim, Minkyung Oh, Soo Kyung Bae, Jae-Gook Shin, Ji-Hong Shon, and Kwang-Hyeon Liu* **986**

- Aldo-Keto Reductase 1C2 Fails to Metabolize Doxorubicin and Daunorubicin in Vitro. *Ryan H. Takahashi, Onkar S. Bains, Tom A. Pfeifer, Thomas A. Grigliatti, Ronald E. Reid, and K. Wayne Riggs* **991**

ARTICLES

- Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/*Abcg2*) in Limiting Brain and Testis Penetration of Xenobiotic Compounds. *Junichi Enokizono, Hiroyuki Kusuhara, Atsushi Ose, Alfred H. Schinkel, and Yuichi Sugiyama* **995**

- Identification of Human Liver Cytochrome P450 Isoforms Involved in Autoinduced Metabolism of the Antiangiogenic Agent (Z)-5-[(1,2-Dihydro-2-oxo-3*H*-indol-3-ylidene)methyl]-2,4-dimethyl-1*H*-pyrrole-3-propanoic Acid (TSU-68). *Ryuichi Kitamura, Hisae Asanoma, Sekio Nagayama, and Masaki Otagiri* **1003**

- Identification and Characterization of Potent CYP2B6 Inhibitors in Woohwangcheongsimwon Suspension, an Herbal Preparation Used in the Treatment and Prevention of Apoplexy in Korea and China. *Hyunmi Kim, Kwon-Bok Kim, Hei-Young Ku, Soo Jin Park, Hoon Choi, Joon-Kwan Moon, Byeoung-Soo Park, Jeong-Han Kim, Sung Su Yea, Choong-Hwan Lee, Hye Suk Lee, Jae-Gook Shin, and Kwang-Hyeon Liu* **1010**

- Comparison of the Bioactivation Potential of the Antidepressant and Hepatotoxin Nefazodone with Aripiprazole, a Structural Analog and Marketed Drug. *Jonathan N. Bauman, Kosea S. Frederick, Aarti Sawant, Robert L. Walsky, Loretta M. Cox, Ronald S. Obach, and Amit S. Kalgutkar* **1016**

- Hepatic Uptake and Excretion of (–)-*N*-{2-[(*R*)-3-(6,7-Dimethoxy-1,2,3,4-tetrahydroisoquinoline-2-carbonyl)piperidino]ethyl}-4-fluorobenzamide (YM758), a Novel If Channel Inhibitor, in Rats and Humans. *Ken-ichi Umehara, Megumi Iwai, Yasuhisa Adachi, Takafumi Iwatsubo, Takashi Usui, and Hidetaka Kamimura* **1030**

- Characterization of Cytochrome P450 Protein Expression along the Entire Length of the Intestine of Male and Female Rats. *Doreen Mitschke, Andreas Reichel, Gert Fricker, and Ursula Moenning* **1039**

- Comparison of Immortalized Fa2N-4 Cells and Human Hepatocytes as in Vitro Models for Cytochrome P450 Induction. *Nireesh Hariparsad, Brian A. Carr, Raymond Evers, and Xiaoyan Chu* **1046**

- The “Albumin Effect” and Drug Glucuronidation: Bovine Serum Albumin and Fatty Acid-Free Human Serum Albumin Enhance the Glucuronidation of UDP-Glucuronosyltransferase (UGT)

Continued on next page

1A9 Substrates but Not UGT1A1 and UGT1A6 Activities. <i>Andrew Rowland, Kathleen M. Knights, Peter I. Mackenzie, and John O. Miners</i>	1056	Genotoxicity Studies. <i>Rozenn Jossé, Caroline Aninat, Denise Glaise, Julie Dumont, Valérie Fessard, Fabrice Morel, Jean-Michel Poul, Christiane Guguen-Guillouzo, and André Guillouzo</i>	1111
ATF5 Is a Highly Abundant Liver-Enriched Transcription Factor that Cooperates with Constitutive Androstane Receptor in the Transactivation of <i>CYP2B6</i> : Implications in Hepatic Stress Responses. <i>Maya Pascual, M. José Gómez-Lechón, José V. Castell, and Ramiro Jover</i>	1063	Role of Flavin-Containing Monooxygenase in Oxidative Metabolism of Voriconazole by Human Liver Microsomes. <i>Souzan B. Yanni, Pieter P. Annaert, Patrick Augustijns, Arlene Bridges, Yan Gao, Daniel K. Benjamin, Jr., and Dhiren R. Thakker</i>	1119
[S] P-Glycoprotein Contributes to the Blood-Brain, but Not Blood-Cerebrospinal Fluid, Barrier in a Spontaneous Canine P-Glycoprotein Knockout Model. <i>Katrina L. Mealey, Stephen Greene, Rodney Bagley, John Gay, Russ Tucker, Patrick Gavin, Kari Schmidt, and Frederick Nelson</i>	1073	Integrated in Vitro Analysis for the in Vivo Prediction of Cytochrome P450-Mediated Drug-Drug Interactions. <i>Dermot F. McGinnity, Nigel J. Waters, James Tucker, and Robert J. Riley</i>	1126
Forkhead Box A2-Mediated Regulation of Female-Predominant Expression of the Mouse <i>Cyp2b9</i> Gene. <i>Tadahiro Hashita, Tsutomu Sakuma, Mami Akada, Asuka Nakajima, Hirofumi Yamahara, Sumiyo Ito, Hidekazu Takesako, and Nobuo Nemoto</i>	1080	Metabolism of Boswellic Acids in Vitro and in Vivo. <i>Phillip Krüger, Rambod Daneshfar, Gunter P. Eckert, Jochen Klein, Dietrich A. Volmer, Ute Bahr, Walter E. Müller, Michael Karas, Manfred Schubert-Zsilavecz, and Mona Abdel-Tawab</i>	1135
Involvement of Multidrug Resistance-Associated Protein 2 (Abcc2) in Molecular Weight-Dependent Biliary Excretion of β -Lactam Antibiotics. <i>Yukio Kato, Seiko Takahara, Sayaka Kato, Yoshiyuki Kubo, Yoshimichi Sai, Ikumi Tamai, Hikaru Yabuuchi, and Akira Tsuji</i>	1088	<i>N</i> -Demethylation Is a Major Route of 2-Amino-3-Methylimidazo[4,5- <i>f</i>]quinoline Metabolism in Mouse. <i>Vijaya M. Lakshmi, Fong Fu Hsu, and Terry V. Zenser</i>	1143
Hydroxyitraconazole, Formed During Intestinal First-Pass Metabolism of Itraconazole, Controls the Time Course of Hepatic CYP3A Inhibition and the Bioavailability of Itraconazole in Rats. <i>Sara K. Quinney, Raymond E. Galinsky, Vanida A. Jiyamapa-Serna, Yong Chen, Mitchell A. Hamman, Stephen D. Hall, and Robert E. Kimura</i>	1097	Predictive Physiologically Based Pharmacokinetic Model for Antibody-Directed Enzyme Prodrug Therapy. <i>Lanyan Fang and Duxin Sun</i>	1153
Role of P-Glycoprotein and the Intestine in the Excretion of DPC 333 [(2 <i>R</i>)-2-[(3 <i>R</i>)-3-Amino-3-[4-(2-methylquinolin-4-ylmethoxy)phenyl]-2-oxopyrrolidin-1-yl]- <i>N</i> -hydroxy-4-methylpentanamide] in Rodents. <i>C. Edwin Garner, Eric Solon, Chii-Ming Lai, Jianrong Lin, Gang Luo, Kevin Jones, Jingwu Duan, Carl P. Decicco, Thomas Maduskuie, Stephen E. Mercer, Lian-Shen Gan, Mingxin Qian, Shimoga Prakash, Huey-Shin Shen, and Frank W. Lee</i>	1102	Comparison of Two Immortalized Human Cell Lines to Study Nuclear Receptor-Mediated CYP3A4 Induction. <i>S. Harmsen, A. S. Koster, J. H. Beijnen, J. H. M. Schellens, and I. Meijerman</i>	1166
Long-Term Functional Stability of Human HepaRG Hepatocytes and Use for Chronic Toxicity and		Intestinal Human Colon Adenocarcinoma Cell Line LS180 Is an Excellent Model to Study Pregnane X Receptor, but Not Constitutive Androstane Receptor, Mediated CYP3A4 and Multidrug Resistance Transporter 1 Induction: Studies with Anti-Human Immunodeficiency Virus Protease Inhibitors. <i>Anshul Gupta, Ganesh M. Mugundu, Pankaj B. Desai, Kenneth E. Thummel, and Jashvant D. Unadkat</i>	1172
		PDZK1 Regulates Two Intestinal Solute Carriers (Slc15a1 and Slc22a5) in Mice. <i>Tomoko Sugiura, Yukio Kato, Tomohiko Wakayama, David L. Silver, Yoshiyuki Kubo, Shoichi Iseki, and Akira Tsuji</i>	1181

[S] Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Immunohistochemical analysis of PEPT1 expression in the small intestine. See article by Sugiura et al. on page 1181 of this issue.

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

Founded by Kenneth C. Leibman—1973

Eric F. Johnson, Editor

ASSOCIATE EDITORS

Stephen D. Hall, Laurence S. Kaminsky, Russell A. Prough, John D. Schuetz, Jeffrey C. Stevens,
Kenneth E. Thummel, Donald J. Tweedie, Steven A. Wrighton, and Garold S. Yost

SCIENTIFIC ADVISORY BOARD

M.W. Anders, Minor J. Coon, Ronald W. Estabrook, Frederick P. Guengerich
James R. Halpert, Anthony Y. Lu, Bettie Sue Masters, and Paul R. Ortiz De Montellano

EDITORIAL BOARD MEMBERS

Tommy B. Andersson	Cornelis J. Elferink	Jeffrey P. Jones	R. Scott Obach	Bill J. Smith
Wayne L. Backes	Michael R. Franklin	Richard Kim	K. Sandy Pang	Grazyna D. Szklarz
Thomas Baillie	Ronald B. Franklin	Sang Geon Kim	Anna Radominska-Pandya	Yun K. Tam
John R. Bend	G. Gordon Gibson	Thomas Kocarek	Judy L. Raucy	Timothy S. Tracy
Jeffrey L. Blumer	Joyce Goldstein	Dennis R. Koop	Allan Rettie	Mary Vore
Kim L.R. Brouwer	Robert Hanzlik	Lawrence H. Lash	Douglas Rickert	Paul B. Watkins
Arthur Cederbaum	Ronald N. Hines	J. Steven Leeder	David S. Riddick	David J. Waxman
Nathan Cherrington	Paul F. Hollenberg	Lois D. Lehman-McKeeman	Joseph K. Ritter	Ronald E. White
Arthur K. Cho	J. Brian Houston	Peter Ian Mackenzie	A. David Rodrigues	Larry C. Wienkers
David D. Christ	Magnus Ingelman-Sundberg	Edward T. Morgan	Melissa Runge-Morris	Paul Wissel
Deepak Dalvie	Philip B. Inskip	Sidney D. Nelson	Magang Shou	Yasushi Yamazoe
William J. Ehlhardt	Margaret O. James			Cheryl L. Zimmerman
Sean Ekins				

BOARD OF PUBLICATIONS TRUSTEES

James E. Barrett, *Chair*; P. Jeffrey Conn, Ross Feldman, Lorraine J. Gudas, Eric F. Johnson, John S. Lazo, Edward T. Morgan, Richard R. Neubig, Rick G. Schnellmann, Darryle D. Schoepp, and Mary Vore

ASPET EXECUTIVE OFFICER: Christine K. Carrico

Journals Director: Richard Dodenhoff

Managing Editor: Jill Filler

Senior Editorial Coordinator: Rhonda Frankenfield

Journal and ASPET office: 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: 301-634-7060; fax: 301-634-7061; email: info@aspet.org; web site: www.aspet.org; journal web site: dmd.aspetjournals.org.

Editorial matters should be addressed to Dr. Eric F. Johnson, Editor, *Drug Metabolism and Disposition*, at the above address.

Official version: The online version of *Drug Metabolism and Disposition* contains all of the information and material contained in the print version plus additional material that may not appear in print such as videos and large data sets. The online version may be more current than the print version. Where noted, the online version has been corrected in departure from the print version. The online version of *Drug Metabolism and Disposition* officially published by the American Society for Pharmacology and Experimental Therapeutics is the definitive version and, to the extent any difference exists, will prevail over the print version.

Instructions to Authors: See jpet.aspetjournals.org for the Instructions to Authors and the ASPET Authorship Responsibility, Financial Disclosure, and Copyright Transfer form.

Subscriptions: Contact the ASPET Subscriptions Dept., 9650 Rockville Pike, Bethesda, MD 20814-3995; telephone: 301-634-7782; fax: 301-634-7061; email: subscriptions@aspet.org. For multi-site and consortia sales in Europe, contact: David Charles, eLicensing, 92 avenue du Général de Gaulle, 78600, Maisons-Laffitte, France; telephone: +33-1-39-12-29-29; fax: +33-1-39-12-47-45; email: dc.licensing@orange.fr.

Change of address: ASPET must be notified 60 days in advance. Copies undeliverable because of incorrect address will be destroyed. Duplicate copies may be obtained, if available, from ASPET at the single copy price. Send address changes to the ASPET office.

Issue replacement policy: *Domestic subscribers*—Claims for nondelivery of issues must be made within three (3) months of issue mail date. *Foreign subscribers*—Claims for nondelivery of issues must be made within six (6)

months of issue mail date. **Missing Issues (domestic and foreign)**—ASPET will not honor refunds or replacement requests made outside of the claim time period. Up to two (2) issues will be replaced free of charge per subscription year.

Reprints in large quantities for commercial or academic use may be purchased from ASPET. For information and prices, call 301-634-7063.

Copyright information: *Drug Metabolism and Disposition* is copyrighted by the American Society for Pharmacology and Experimental Therapeutics. For permission to photocopy or use material electronically from *Drug Metabolism and Disposition*, see www.copyright.com or contact the Copyright Clearance Center (CCC), Inc., 222 Rosewood Dr., Danvers, MA 01923; telephone: 978-750-8400. Photocopying of articles beyond that permitted by Sections 107 and 108 of the U.S. Copyright Law is allowed, provided that the \$20.00-per-copy fee is paid through the CCC. Classroom photocopying is permitted at no fee, provided that students are not charged more than the cost of duplication. This consent does not extend to other kinds of copying. Reproduction of any portion of an article for subsequent republication requires permission of ASPET. Write to the ASPET office at the above address. Requests should include a statement of intended use as well as explicit specifications of the materials to be reproduced.

Disclaimer: The statements and opinions contained in the articles of *Drug Metabolism and Disposition* are solely those of the individual authors and contributors and not of the American Society for Pharmacology and Experimental Therapeutics. The appearance of advertisements in the journal is not a warranty, endorsement, or approval of the products or their safety. The American Society for Pharmacology and Experimental Therapeutics disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in any article or advertisement.

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics. All rights reserved. Printed in the U.S.A.



WE ARE PHARMACOLOGISTS

The Federation of American Societies for Experimental Biology is a coalition of life science societies dedicated to enhancing the quality of life through research. If you are a member of the American Society for Pharmacology and Experimental

Therapeutics you—like more than 65,000 other scientists—are a member of FASEB. FASEB strives to provide support in public affairs, distinguished publications, invaluable meetings and conferences, and a variety of member services.

FASEB—we are life scientists and we work for you. www.faseb.org

FASEB



Announces:

Training Opportunities for Graduate Students and PhDs

NIGMS Summer Short Courses in Integrative and Organ Systems Science

The National Institute of General Medical Sciences (NIGMS) is funding four summer short courses that provide specialized training for using intact organ system and in vivo animal models in the conduct of research. The purpose of each short course is to introduce graduate students and Ph.Ds to the knowledge and skills needed for integrative studies of organ systems and intact animals, and the physiological and biochemical responses of these systems to drugs. These critical skills are in short supply. Graduate students and Ph.Ds. with these skills are in great demand in both academic and industrial settings. Summer Short Courses in Integrative and Organ Systems Science are available at Michigan State University, University of California at San Diego, University of Nebraska Medical Center, and the University of North Carolina at Chapel Hill.

Knock-Out Mice



Animal Models



ASPET-Integrative Organ Systems Sciences(IOSS) Fund

The ASPET-IOSS Fund was created to provide support for graduate students and post-doctoral researchers seeking training in integrative, whole organ systems sciences. The ASPET-IOSS Fund will augment developing programs that provide training of students in integrative, whole organ systems sciences. The ASPET-IOSS Fund hopes to contribute to developing infrastructure to sustain and expand training in this critical area of research. Applications will be reviewed upon receipt and on a continuing basis. The ASPET-IOSS Awards are primarily available to support graduate students and post-docs who participate in an industry sponsored internship that furthers the students' training and exposure to integrative, whole organ biology.

For details and inquiries about the NIGMS Summer Short Course Programs and the ASPET-IOSS Fund, visit the ASPET website at:

http://www.aspet.org/public/public_affairs/pa_ioss.html